According to an April 15, 2026 analysis by KFF Health News, employer-sponsored health insurance (ESI) remained the dominant source of coverage for U.S. residents under age 65 in 2025, covering about 60% of that group , roughly 165.6 million people. A separate KFF review of the American Community Survey placed the number slightly lower, at 154 million, using a hierarchy that counts individuals with multiple forms of coverage only once. ESI is typically delivered through insured plans purchased from state-licensed carriers or, more commonly among large employers, through self-funded arrangements backed by stop-loss insurance. Its reach and structure fall under the Employee Retirement Income Security Act (ERISA), which treats employer health benefits as employee benefit plans subject to disclosure and fiduciary oversight.
This snapshot shows how firmly the U.S. health financing system still leans on workplace coverage. The 60% figure, mostly steady even amid labor churn, means any change in premiums, stop-loss pricing, or ERISA rulemaking sends quick shockwaves through benefits budgets and insurer margins. For consultants and PBM strategists, the persistent split by income and firm size keeps the market fragmented: large employers stay nimble under self-funding while smaller firms struggle with cost growth that often pushes employees toward exchanges or Medicaid. That imbalance keeps demand alive for level-funded hybrids and captive structures , options that blur the line between fully insured and self-funded. Honestly, it’s hard to see that divide narrowing anytime soon.
Heading into 2026, the bigger shift looks to be in plan design, not enrollment. Claim volatility, predictive analytics, and the normalization of digital health reimbursement are steering more mid-market employers toward layered stop-loss protection. For insurers, that evolution changes where the money comes from , less from underwriting, more from administrative and service revenue. The open question is regulatory: any move to weaken ERISA’s federal preemption would ripple through every benefit administrator, network contract, and transparency program tracked on RxBenefits.ai. Nobody really knows yet whether regulators have the appetite for that fight, but the industry is bracing either way.
